Topline data from SURMOUNT-MMOE cardiovascular outcomes trial expected 2025.

window · Jan 1, 2025

Phase 3 TRIUMPH readouts expected 2026-2027.

window · Jan 1, 2026

REDEFINE 1 topline readout anticipated in 2025.

window · Jan 1, 2025

FDA action on MACE risk reduction indication based on SELECT trial.

window · Jan 1, 2024

Phase 2 obesity readout expected second half of 2024.

window · Sep 1, 2024

Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.

window · Jan 1, 2025